Acadia Pharmaceuticals (NASDAQ:ACAD) is at a critical juncture. Its two key products show strong sales, but regulatory hurdles in Europe loom.
NUPLAZID for Parkinson's psychosis and DAYBUE for Rett syndrome are driving growth. Acadia is expanding its sales force by 30%.
The European CHMP may issue a negative opinion for DAYBUE, delaying EU market access. The company will seek re-examination.
Financial metrics: market cap $3.65B, P/E 9.74, PEG 0.16. The stock appears undervalued.
Phase 2 data for remlifanserin in Alzheimer's psychosis expected mid-2026.
